Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines.

Bartolini M, Marco-Contelles J.

Chem Rec. 2018 Nov 29. doi: 10.1002/tcr.201800155. [Epub ahead of print] Review.

PMID:
30489012
2.

Regulation of biofilm aging and dispersal in Bacillus subtilis by the alternative sigma factor SigB.

Bartolini M, Cogliati S, Vileta D, Bauman C, Rateni L, Leñini C, Argañaraz F, Francisco M, Villalba JM, Steil L, Völker U, Grau R.

J Bacteriol. 2018 Nov 5. pii: JB.00473-18. doi: 10.1128/JB.00473-18. [Epub ahead of print]

PMID:
30396900
3.

New insights into the altered binding capacity of pharmaceutical-grade human serum albumin: site-specific binding studies by induced circular dichroism spectroscopy.

Tramarin A, Tedesco D, Naldi M, Baldassarre M, Bertucci C, Bartolini M.

J Pharm Biomed Anal. 2019 Jan 5;162:171-178. doi: 10.1016/j.jpba.2018.09.022. Epub 2018 Sep 12.

PMID:
30248608
4.

Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire.

Raggi A, Covelli V, Guastafierro E, Leonardi M, Scaratti C, Grazzi L, Bartolini M, Viticchi G, Cevoli S, Pierangeli G, Tedeschi G, Russo A, Barbanti P, Aurilia C, Lovati C, Giani L, Frediani F, Di Fiore P, Bono F, Rapisarda L, D'Amico D.

J Headache Pain. 2018 Sep 10;19(1):85. doi: 10.1186/s10194-018-0914-7.

5.

Immobilized enzyme-based analytical tools in the -omics era: Recent advances.

Naldi M, Tramarin A, Bartolini M.

J Pharm Biomed Anal. 2018 Oct 25;160:222-237. doi: 10.1016/j.jpba.2018.07.051. Epub 2018 Jul 31. Review.

PMID:
30099294
6.

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.

Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML.

J Med Chem. 2018 Sep 13;61(17):7640-7656. doi: 10.1021/acs.jmedchem.8b00610. Epub 2018 Aug 24.

PMID:
30078314
7.

Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease.

Rampa A, Bartolini M, Pruccoli L, Naldi M, Iriepa I, Moraleda I, Belluti F, Gobbi S, Tarozzi A, Bisi A.

Molecules. 2018 Jul 30;23(8). pii: E1902. doi: 10.3390/molecules23081902.

8.

Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.

Chioua M, Buzzi E, Moraleda I, Iriepa I, Maj M, Wnorowski A, Giovannini C, Tramarin A, Portali F, Ismaili L, López-Alvarado P, Bolognesi ML, Jóźwiak K, Menéndez JC, Marco-Contelles J, Bartolini M.

Eur J Med Chem. 2018 Jul 15;155:839-846. doi: 10.1016/j.ejmech.2018.06.044. Epub 2018 Jun 19.

PMID:
29958119
9.

Intracranial haemorrhage: the role of a pre-existing headache.

Viticchi G, Fiori C, Acciarri MC, Falsetti L, Buratti L, Silvestrini M, Provinciali L, Bartolini M.

Neurol Sci. 2018 Jun;39(Suppl 1):97-98. doi: 10.1007/s10072-018-3380-8. No abstract available.

PMID:
29904867
10.

The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire.

Covelli V, Guastafierro E, Raggi A, Grazzi L, Leonardi M, Scaratti C, Bartolini M, Viticchi G, Cevoli S, Pierangeli G, Tedeschi G, Russo A, Barbanti P, Aurilia C, Lovati C, Giani L, Fredian F, Di Fiore P, Bono F, Rapisarda L, D'Amico D.

Neurol Sci. 2018 Jun;39(Suppl 1):131-133. doi: 10.1007/s10072-018-3363-9. No abstract available.

PMID:
29904835
11.

Migraine: incorrect self-management for a disabling disease.

Viticchi G, Falsetti L, Bartolini M, Buratti L, Ulissi A, Baldassari M, Provinciali L, Silvestrini M.

Neurol Int. 2018 Apr 4;10(1):7510. doi: 10.4081/ni.2018.7510. eCollection 2018 Mar 30.

12.

A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.

Andrisano V, Naldi M, De Simone A, Bartolini M.

Expert Opin Ther Pat. 2018 Jun;28(6):455-465. doi: 10.1080/13543776.2018.1476494. Review.

PMID:
29757691
13.

Combination of human acetylcholinesterase and serum albumin sensing surfaces as highly informative analytical tool for inhibitor screening.

Fabini E, Tramarin A, Bartolini M.

J Pharm Biomed Anal. 2018 Jun 5;155:177-184. doi: 10.1016/j.jpba.2018.03.060. Epub 2018 Mar 31.

PMID:
29635172
14.

Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.

Galdeano C, Coquelle N, Cieslikiewicz-Bouet M, Bartolini M, Pérez B, Clos MV, Silman I, Jean L, Colletier JP, Renard PY, Muñoz-Torrero D.

Molecules. 2018 Mar 11;23(3). pii: E634. doi: 10.3390/molecules23030634.

15.

Neurocognitive functioning and cerebrovascular reactivity after carotid endarterectomy.

Lattanzi S, Carbonari L, Pagliariccio G, Bartolini M, Cagnetti C, Viticchi G, Buratti L, Provinciali L, Silvestrini M.

Neurology. 2018 Jan 23;90(4):e307-e315. doi: 10.1212/WNL.0000000000004862. Epub 2017 Dec 27.

PMID:
29282326
16.

New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation.

Pandolfi F, De Vita D, Bortolami M, Coluccia A, Di Santo R, Costi R, Andrisano V, Alabiso F, Bergamini C, Fato R, Bartolini M, Scipione L.

Eur J Med Chem. 2017 Dec 1;141:197-210. doi: 10.1016/j.ejmech.2017.09.022. Epub 2017 Sep 18.

PMID:
29031067
17.

Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.

De Simone A, Bartolini M, Baschieri A, Apperley KYP, Chen HH, Guardigni M, Montanari S, Kobrlova T, Soukup O, Valgimigli L, Andrisano V, Keillor JW, Basso M, Milelli A.

Eur J Med Chem. 2017 Oct 20;139:378-389. doi: 10.1016/j.ejmech.2017.07.058. Epub 2017 Jul 25.

PMID:
28810189
18.

New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.

Roldán-Peña JM, Alejandre-Ramos D, López Ó, Maya I, Lagunes I, Padrón JM, Peña-Altamira LE, Bartolini M, Monti B, Bolognesi ML, Fernández-Bolaños JG.

Eur J Med Chem. 2017 Sep 29;138:761-773. doi: 10.1016/j.ejmech.2017.06.048. Epub 2017 Jun 27.

PMID:
28728108
19.

Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.

Simoni E, Bartolini M, Abu IF, Blockley A, Gotti C, Bottegoni G, Caporaso R, Bergamini C, Andrisano V, Cavalli A, Mellor IR, Minarini A, Rosini M.

Future Med Chem. 2017 Jun;9(10):953-963. doi: 10.4155/fmc-2017-0039. Epub 2017 Jun 20.

PMID:
28632446
20.

Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.

Pérez-Areales FJ, Betari N, Viayna A, Pont C, Espargaró A, Bartolini M, De Simone A, Rinaldi Alvarenga JF, Pérez B, Sabate R, Lamuela-Raventós RM, Andrisano V, Luque FJ, Muñoz-Torrero D.

Future Med Chem. 2017 Jun;9(10):965-981. doi: 10.4155/fmc-2017-0049. Epub 2017 Jun 20.

PMID:
28632395
21.

Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.

Viticchi G, Falsetti L, Buratti L, Sajeva G, Luzzi S, Bartolini M, Provinciali L, Silvestrini M.

J Alzheimers Dis. 2017;59(1):67-75. doi: 10.3233/JAD-170160.

PMID:
28582863
22.

Raven coloured progressive matrices in migraine without aura patients.

Viticchi G, Falsetti L, Bartolini M, Buratti L, Pistelli L, Provinciali L, Silvestrini M.

Neurol Sci. 2017 May;38(Suppl 1):177-179. doi: 10.1007/s10072-017-2898-5.

PMID:
28527091
23.

Chalcone-based carbamates for Alzheimer's disease treatment.

Rampa A, Montanari S, Pruccoli L, Bartolini M, Falchi F, Feoli A, Cavalli A, Belluti F, Gobbi S, Tarozzi A, Bisi A.

Future Med Chem. 2017 May;9(8):749-764. doi: 10.4155/fmc-2017-0029. Epub 2017 May 12.

PMID:
28498775
24.

Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis.

Naldi M, Baldassarre M, Domenicali M, Bartolini M, Caraceni P.

J Pharm Biomed Anal. 2017 Sep 10;144:138-153. doi: 10.1016/j.jpba.2017.04.023. Epub 2017 Apr 18. Review.

PMID:
28465079
25.

5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor.

Wang L, Moraleda I, Iriepa I, Romero A, López-Muñoz F, Chioua M, Inokuchi T, Bartolini M, Marco-Contelles J.

Medchemcomm. 2017 Apr 28;8(6):1307-1317. doi: 10.1039/c7md00143f. eCollection 2017 Jun 1.

26.

Microbial flora, probiotics, Bacillus subtilis and the search for a long and healthy human longevity.

Ayala FR, Bauman C, Cogliati S, Leñini C, Bartolini M, Grau R.

Microb Cell. 2017 Mar 16;4(4):133-136. doi: 10.15698/mic2017.04.569.

27.

Targeting the Nrf2/Amyloid-Beta Liaison in Alzheimer's Disease: A Rational Approach.

Simoni E, Serafini MM, Caporaso R, Marchetti C, Racchi M, Minarini A, Bartolini M, Lanni C, Rosini M.

ACS Chem Neurosci. 2017 Jul 19;8(7):1618-1627. doi: 10.1021/acschemneuro.7b00100. Epub 2017 Apr 25.

PMID:
28421738
28.

Towards automation in protein digestion: Development of a monolithic trypsin immobilized reactor for highly efficient on-line digestion and analysis.

Naldi M, Černigoj U, Štrancar A, Bartolini M.

Talanta. 2017 May 15;167:143-157. doi: 10.1016/j.talanta.2017.02.016. Epub 2017 Feb 5.

PMID:
28340705
29.

Transcriptional regulation of adhesive properties of Bacillus subtilis to extracellular matrix proteins through the fibronectin-binding protein YloA.

Rodriguez Ayala F, Bauman C, Bartolini M, Saball E, Salvarrey M, Leñini C, Cogliati S, Strauch M, Grau R.

Mol Microbiol. 2017 Jun;104(5):804-821. doi: 10.1111/mmi.13666. Epub 2017 Mar 27.

30.

O040. Migraineurs and self-consciousness of illness in a population of hospital workers.

Viticchi G, Falsetti L, Buratti L, Plutino A, Provinciali L, Silvestrini M, Bartolini M.

J Headache Pain. 2015 Dec;16(Suppl 1):A71. doi: 10.1186/1129-2377-16-S1-A71. No abstract available.

31.

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice.

Paolucci M, Altavilla R, Gambale G, Altamura C, Viticchi G, Bartolini M, Silvestrini M, Vernieri F.

J Headache Pain. 2015 Dec;16(Suppl 1):A117. doi: 10.1186/1129-2377-16-S1-A117. No abstract available.

32.

Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.

Jeřábek J, Uliassi E, Guidotti L, Korábečný J, Soukup O, Sepsova V, Hrabinova M, Kuča K, Bartolini M, Peña-Altamira LE, Petralla S, Monti B, Roberti M, Bolognesi ML.

Eur J Med Chem. 2017 Feb 15;127:250-262. doi: 10.1016/j.ejmech.2016.12.048. Epub 2016 Dec 26.

PMID:
28064079
33.

Polyamine Conjugation as a Promising Strategy To Target Amyloid Aggregation in the Framework of Alzheimer's Disease.

Simoni E, Caporaso R, Bergamini C, Fiori J, Fato R, Miszta P, Filipek S, Caraci F, Giuffrida ML, Andrisano V, Minarini A, Bartolini M, Rosini M.

ACS Med Chem Lett. 2016 Sep 26;7(12):1145-1150. eCollection 2016 Dec 8.

34.

CT image quality assessment by a Channelized Hotelling Observer (CHO): Application to protocol optimization.

Noferini L, Taddeucci A, Bartolini M, Bruschi A, Menchi I.

Phys Med. 2016 Dec;32(12):1717-1723. doi: 10.1016/j.ejmp.2016.11.002. Epub 2016 Dec 10.

PMID:
27964873
35.

Uleine Disrupts Key Enzymatic and Non-Enzymatic Biomarkers that Leads to Alzheimer's Disease.

Seidl C, de Moraes Santos CA, De Simone A, Bartolini M, Weffort-Santos AM, Andrisano V.

Curr Alzheimer Res. 2017;14(3):317-326. doi: 10.2174/1567205013666161026150455.

PMID:
27784218
36.

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.

Montanari S, Scalvini L, Bartolini M, Belluti F, Gobbi S, Andrisano V, Ligresti A, Di Marzo V, Rivara S, Mor M, Bisi A, Rampa A.

J Med Chem. 2016 Jul 14;59(13):6387-406. doi: 10.1021/acs.jmedchem.6b00609. Epub 2016 Jun 28.

PMID:
27309570
37.

Glycosylated Hemoglobin and Functional Outcome after Acute Ischemic Stroke.

Lattanzi S, Bartolini M, Provinciali L, Silvestrini M.

J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1786-1791. doi: 10.1016/j.jstrokecerebrovasdis.2016.03.018. Epub 2016 Apr 18.

PMID:
27103269
38.

Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy.

Boulebd H, Ismaili L, Bartolini M, Bouraiou A, Andrisano V, Martin H, Bonet A, Moraleda I, Iriepa I, Chioua M, Belfaitah A, Marco-Contelles J.

Molecules. 2016 Mar 24;21(4):400. doi: 10.3390/molecules21040400.

39.

Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease.

Prati F, Bergamini C, Fato R, Soukup O, Korabecny J, Andrisano V, Bartolini M, Bolognesi ML.

ChemMedChem. 2016 Jun 20;11(12):1284-95. doi: 10.1002/cmdc.201600014. Epub 2016 Feb 16.

PMID:
26880501
40.

Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease.

Lemes LFN, de Andrade Ramos G, de Oliveira AS, da Silva FMR, de Castro Couto G, da Silva Boni M, Guimarães MJR, Souza INO, Bartolini M, Andrisano V, do Nascimento Nogueira PC, Silveira ER, Brand GD, Soukup O, Korábečný J, Romeiro NC, Castro NG, Bolognesi ML, Romeiro LAS.

Eur J Med Chem. 2016 Jan 27;108:687-700. doi: 10.1016/j.ejmech.2015.12.024. Epub 2015 Dec 17.

PMID:
26735910
41.

Acute Occlusion of the Percheron Artery during Pregnancy: A Case Report and a Review of the Literature.

Viticchi G, Falsetti L, Fiori C, Jorio G, Plutino A, Buratti L, Bartolini M, Silvestrini M.

J Stroke Cerebrovasc Dis. 2016 Mar;25(3):572-7. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.011. Epub 2015 Dec 11. Review.

PMID:
26698643
42.

Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography.

Zha X, Lamba D, Zhang L, Lou Y, Xu C, Kang D, Chen L, Xu Y, Zhang L, De Simone A, Samez S, Pesaresi A, Stojan J, Lopez MG, Egea J, Andrisano V, Bartolini M.

J Med Chem. 2016 Jan 14;59(1):114-31. doi: 10.1021/acs.jmedchem.5b01119. Epub 2015 Dec 29.

PMID:
26632651
43.

Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.

Montanari S, Bartolini M, Neviani P, Belluti F, Gobbi S, Pruccoli L, Tarozzi A, Falchi F, Andrisano V, Miszta P, Cavalli A, Filipek S, Bisi A, Rampa A.

ChemMedChem. 2016 Jun 20;11(12):1296-308. doi: 10.1002/cmdc.201500392. Epub 2015 Oct 28.

PMID:
26507467
44.

Nature-Inspired Multifunctional Ligands: Focusing on Amyloid-Based Molecular Mechanisms of Alzheimer's Disease.

Simoni E, Serafini MM, Bartolini M, Caporaso R, Pinto A, Necchi D, Fiori J, Andrisano V, Minarini A, Lanni C, Rosini M.

ChemMedChem. 2016 Jun 20;11(12):1309-17. doi: 10.1002/cmdc.201500422. Epub 2015 Oct 26.

PMID:
26497622
45.

Framingham risk score can predict cognitive decline progression in Alzheimer's disease.

Viticchi G, Falsetti L, Buratti L, Boria C, Luzzi S, Bartolini M, Provinciali L, Silvestrini M.

Neurobiol Aging. 2015 Nov;36(11):2940-2945. doi: 10.1016/j.neurobiolaging.2015.07.023. Epub 2015 Jul 26.

PMID:
26279114
46.

Triptan use among hospital workers affected by migraine.

Viticchi G, Falsetti L, Buratti L, Plutino A, Provinciali L, Silvestrini M, Bartolini M.

Neurol Sci. 2015 May;36 Suppl 1:157-9. doi: 10.1007/s10072-015-2143-z.

PMID:
26017534
47.

From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold.

Rampa A, Mancini F, De Simone A, Falchi F, Belluti F, Di Martino RM, Gobbi S, Andrisano V, Tarozzi A, Bartolini M, Cavalli A, Bisi A.

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2804-8. doi: 10.1016/j.bmcl.2015.05.002. Epub 2015 May 9.

PMID:
26003339
48.

Metabolic syndrome and cerebrovascular impairment in Alzheimer's disease.

Viticchi G, Falsetti L, Buratti L, Luzzi S, Bartolini M, Acciarri MC, Provinciali L, Silvestrini M.

Int J Geriatr Psychiatry. 2015 Dec;30(12):1164-70. doi: 10.1002/gps.4269. Epub 2015 Mar 5.

PMID:
25754252
49.

Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids.

Benchekroun M, Bartolini M, Egea J, Romero A, Soriano E, Pudlo M, Luzet V, Andrisano V, Jimeno ML, López MG, Wehle S, Gharbi T, Refouvelet B, de Andrés L, Herrera-Arozamena C, Monti B, Bolognesi ML, Rodríguez-Franco MI, Decker M, Marco-Contelles J, Ismaili L.

ChemMedChem. 2015 Mar;10(3):523-39. doi: 10.1002/cmdc.201402409. Epub 2014 Dec 23.

PMID:
25537267
50.

From the dual function lead AP2238 to AP2469, a multi-target-directed ligand for the treatment of Alzheimer's disease.

Tarozzi A, Bartolini M, Piazzi L, Valgimigli L, Amorati R, Bolondi C, Djemil A, Mancini F, Andrisano V, Rampa A.

Pharmacol Res Perspect. 2014 Apr;2(2):e00023. doi: 10.1002/prp2.23. Epub 2014 Mar 24.

Supplemental Content

Loading ...
Support Center